[1] OLVERA A, CORTEY M, SEGALÉS J. Molecular evolution of porcine circovirus type 2 genomes:phylogeny and clonality[J]. Virology, 2007, 357(2):175-185.
[2] ELLIS J. Porcine circovirus:a historical perspective[J]. Vet Pathol, 2014, 51(2):315-327.
[3] SEO H W, HAN K, PARK C, et al. Clinical, virological, immunological and pathological evaluation of four porcine circovirus type 2 vaccines[J]. Vet J, 2014, 200(1):65-70.
[4] BEACH N M, MENG X J. Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2(PCV2)[J]. Virus Res, 2012, 164(1-2):33-42.
[5] 徐磊,宁蓬勃,郭抗抗,等. 猪圆环病毒2型疫苗研究进展[J]. 动物医学进展, 2012, 33(10):64-70.
XU L, NING P B, GUO K K, et al. Research progress on porcine circovirus type 2 vaccine[J]. Progress in Veterinary Medicine, 2012, 33(10):64-70. (in Chinese)
[6] GAVA D, SERRÃO V H B, FERNANDES L T, et al. Structure analysis of capsid protein of Porcine circovirus type 2 from pigs with systemic disease[J]. Braz J Microbiol, 2018, 49(2):351-357.
[7] OPRIESSNIG T, GERBER P F, XIAO C T, et al. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2[J]. Vaccine, 2014, 32(34):4342-4348.
[8] KEKARAINEN T, SEGALÉS J. Porcine circovirus 2 immunology and viral evolution[J]. Porcine Health Manag, 2015, 1(1):17.
[9] SCHILLER J T, LOWY D R. Raising expectations for subunit vaccine[J]. J Infect Dis, 2014, 211(9):1373-1375.
[10] LI W L, WANG X W, BAI J, et al. Construction and immunogenicity of recombinant porcine circovirus-like particles displaying somatostatin[J]. Vet Microbiol, 2013, 163(1-2):23-32.
[11] 付强,程立坤,董林,等. 猪圆环病毒Cap蛋白亚单位疫苗研究进展[J]. 畜牧与兽医, 2015, 47(3):117-120.
FU Q, CHENG L K, DONG L, et al. Advances in research on porcine circovirus Cap protein subunit vaccine[J]. Animal Husbandry & Veterinary Medicine, 2015, 47(3):117-120. (in Chinese)
[12] DING J, ZHANG C L, GAO M J, et al. Enhanced porcine circovirus Cap protein production by Pichia pastoris with a fuzzy logic DO control based methanol/sorbitol co-feeding induction strategy[J]. J Biotechnol, 2014, 177:35-44.
[13] WELLS E, ROBINSON A S. Cellular engineering for therapeutic protein production:product quality, host modification, and process improvement[J]. Biotechnol J, 2017, 12(1):1600105.
[14] WURM F M, HACKER D. First CHO genome[J]. Nat Biotechnol, 2011, 29(8):718-720.
[15] LI F, VIJAYASANKARAN N, SHEN A Y, et al. Cell culture processes for monoclonal antibody production[J]. mAbs, 2010, 2(5):466-479.
[16] RAJENDRA Y, HOUGLAND M D, ALAM R, et al. A high cell density transient transfection system for therapeutic protein expression based on a CHO GS-knockout cell line:process development and product quality assessment[J]. Biotechnol Bioeng, 2015, 112(5):977-986.
[17] BETTS Z, DICKSON A J. Improved CHO cell line stability and recombinant protein expression during long-term culture[M]//MELEADY P. Heterologous Protein Production in CHO Cells. New York, NY:Humana Press, 2017:119-141.
[18] 王一平, 郭龙军,唐青海,等. 猪圆环病毒2型疫苗的研究进展[J]. 畜牧兽医学报, 2012, 43(9):1337-1345.
WANG Y P, GUO L J, TANG Q H, et al. Research progress on vaccine of porcine circovirus type 2[J]. Acta Veterinaria et Zootechnica Sinica, 2012, 43(9):1337-1345. (in Chinese)
[19] 杨利勇, 李春凤. 猪圆环病毒2型在我国的流行及疫苗研究现状[J]. 畜牧与兽医, 2015, 47(4):132-134.
YANG L Y, LI C F. Current status of porcine circovirus type 2 in China and vaccine research[J]. Animal Husbandry & Veterinary Medicine, 2015, 47(4):132-134. (in Chinese)
[20] POPP O, MOSER S, ZIELONKA J, et al. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function[J]. mAbs, 2018, 10(2):290-303.
[21] 张薇,闫琰,白鲁根,等. 稳定表达犬转铁蛋白受体CHO细胞系的建立和鉴定[J]. 四川大学学报:医学版, 2017, 48(1):57-60, 80.
ZHANG W, YAN Y, BAI L G, et al. The establishment and identification of stable CHO cell line with canine transferrin receptor expression[J]. Journal of Sichuan University:Medical Science Edition, 2017, 48(1):57-60, 80. (in Chinese)
[22] YU W T, ZHAN Y, XUE B X, et al. Highly efficient cellular uptake of a cell-penetrating peptide (CPP) derived from the capsid protein of porcine circovirus type 2[J]. J Biol Chem, 2018, 293(39):15221-15232. |